Metraipolis › archive › dc_bafd061981f0

Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity — Europe PMC PMID:41797776

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41797776
DOI
10.3389/fmed.2026.1754490
License (as archived)
solo-consultazione
Archived
2026-11-05T15:27:26.760Z
SHA-256 of the archived text
97ee4848405dc16261e15620658858f74a4249112bd7962e161cfa334dc71a98
Stable URL of this page
https://metraipolis.com/documento/dc_bafd061981f0

How to cite

Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity — Europe PMC PMID:41797776 — Europe PMC (en), https://europepmc.org/article/MED/41797776 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bafd061981f0 (Metraipolis archive dc_bafd061981f0, sha256 97ee4848405dc16261e15620658858f74a4249112bd7962e161cfa334dc71a98)
BibTeX
@misc{dcbafd061981f0,
  title = {Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity — Europe PMC PMID:41797776},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41797776},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bafd061981f0; sha256 97ee4848405dc16261e15620658858f74a4249112bd7962e161cfa334dc71a98},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41797776. Agents can read the archived copy with the MCP tool read_document.